Curia Biologics

Home | Curia Biologics | Discovery | Antibody Discovery & Engineering | Beacon

Beacon

Curia proudly offers the Bruker Beacon® Optofluidic System for a rapid, high-throughput, AI-driven approach to advance antibody-based drug discovery.

Work with individual cells

significantly faster than using other technologies

Clones identified

with >50% faster timelines*

Track

monoclonal antibody function and sequence from the initial screen

Automate

and scale workflows far beyond manual, time-intensive analysis

Integrated Pipeline

for hit-to-lead identification, optimization, and assay development

Target to Lead Antibodies in Just Weeks

Curia’s single B cell cloning workflow enables high-resolution screening with unprecedented speed.

  • Directly assess tens of thousands of individual B cells
  • Generate diverse hit panels
  • Recover re-expressed lead molecules
  • Accelerate time to clinic

State-of-the-art technology and most advanced single B cell screening workflows

  • Screen and identify potentially thousands of hit monoclonal antibodies using up to 80,000 NanoPen® chambers per workflow.
  • Next generation sequencing for barcoded BCR sequences facilitates quick, high-throughput sequence recovery.
  • Bioinformatics determine sequence diversity and developability. Once threshold plasma titers are reached, hit sequences are returned in just six to twenty days!

Import B cells into Beacon® system

Sort tens of thousands of single B cells into NanoPen® chambers

Automate screening and barcoded cDNA synthesis to initiate sequence recovery

Prepare multiplexed libraries for next generation sequencing

Custom bioinformatics analysis of mAb diversity and developability

Rapidly re-express mAbs for validation and characterization

High-throughput recombinant expression for sophisticated characterization

A complete workflow for antibody discovery and drug development

Save time and money with an end-to-end workflow that quickly identifies relevant antibodies and provides a seamless path to developing humanized antibodies – in a six-month timeframe or less.

In addition to deploying the Beacon system to identify and select cells of interest, Curia accelerates “First-to-Human” workflows with everything you need to successfully bring a new drug to the clinic, including:

The PentaMice® platform offers superior immunological diversity.

  • Five WT strains that cover nine distinct MHC haplotypes, two mice per strain in each set
  • Achieve maximum plasma titers and boost the opportunity to generate high-quality antibodies in vivo
  • Years of humanization expertise and 1,000+ humanized variants delivered
  • Own your own molecules: royalty-free and milestone-free

We work with all major human antibody-producing transgenic mouse platforms and specialized genetically modified strains, as well as specialized knockout mice. Clients simply arrange to have the animals shipped to our AAALAC-accredited vivarium for antibody discovery projects.

To quickly generate gram quantities of a unique antibody for further evaluation, Curia utilizes recombinant production (CHO) and delivers a straight path from development to GMP manufacturing.

  • Proprietary CHO platforms offer high performance.
  • TunaCHO℠ transient platform has yields as high as 2 g/L.
  • CHO-GSN℠ stable platform offers robust performance as high as 7 g/L.
  • All platforms are ready for commercialization
  • Royalty-free licensing is available.

Save time and resources by using our fully integrated antibody engineering service to reformat lead antibodies to your desired specifications (e.g. scFv or bi-specific). We can also deliver customized viral constructs and engineered cell lines to support CAR-T development and beyond.

Antibody discovery is all about starting with a large pool of possibilities and mitigating risk at every step. Our use of the PentaMice platform provides maximum immunologic diversity early on, so you start with a complex pool of antibodies that have already undergone endogenous in vivo affinity maturation. Then the Beacon system delivers clonal paired antibody sequences from hits right from the start, focusing your program on the antibodies that matter.

Margaret Ho | General Manager and Site Head, Curia Hayward

Save time and money, accelerate workflows with Curia and the Beacon® system

0  +
antibodies
100-1,152
mAb sequences
48-96
lead candidates
12-16 weeks
beacon advantage

The Bruker Beacon® Optofluidic System Advantage

  • Speed: Curia’s full campaign workflow can take 6-months or less*; time to mAb sequences post immunization in only 6-20 days.
  • Scale: Larger screening pool; a single workflow screens ~10-50K mAbs (vs. ~3-10K mAbs for traditional hybridoma or the Beacon system with AbD 2.0 workflows)
  • Clonal: Curia’s single B cell discovery workflow directly identifies monoclonal antibodies from the outset

Expanded Antibody Discovery at Curia